Clinical Scorecard: Utilization of Mesenchymal Stem Cells and Their Exosomes in Treating Pediatric ARDS: A Review of Translational Research and Evolving Nursing Responsibilities

At a Glance

Key Highlights

• MSCs and MSC-Exos show promise in treating pediatric ARDS.
• Therapeutic effects are primarily through immunomodulation and paracrine signaling.
• Nursing roles are evolving to include advanced management of biotherapeutic modalities.
• MSC-Exos have advantages such as lower immunogenicity and enhanced stability.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of pediatric ARDS should be based on clinical criteria and imaging findings.

Management

• Current management includes supportive care, lung-protective ventilation, and exploration of MSC and MSC-Exos therapies.

Monitoring & Follow-up

• Monitor for infusion reactions and lympho-immune dysregulation during MSC and MSC-Exos therapies.

Risks

• Potential risks include infusion reactions and complications related to the use of live biological products.

Patient & Prescribing Data

Pediatric patients with severe ARDS requiring advanced therapeutic interventions.

MSCs and MSC-Exos may modulate immune responses and enhance tissue repair in pediatric ARDS.

Clinical Best Practices

• Ensure a competent nursing workforce for the safe delivery of MSC and MSC-Exos therapies.
• Integrate holistic education and psychosocial support for patients and families in experimental treatment situations.
• Adopt a standardized approach to the implementation of advanced cell therapies in clinical practice.

Related Resources & Content

• Source Article